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Introduction {#sec1}
============

Bone marrow stromal cells (BMSCs) are multi-potent progenitor cells with self-renewal capabilities and multi-lineage differentiation potentials, including osteogenesis and adipogenesis ([@bib4], [@bib36], [@bib38], [@bib46]). The relation between osteogenesis and adipogenesis in BMSCs is critical for normal bone homeostasis. Skewed cell fate of BMSCs can lead to developmental defects. For example, inhibition of adipogenesis may enhance bone growth and repair ([@bib18], [@bib20]). More recently, Mendez-Ferrer and others reported that the final cell-fate decision of BMSCs relies on an orchestrated activation of lineage-specific genes and repression of genes governing cell stemness or commitment to other lineages ([@bib21], [@bib34], [@bib41]).

Bohring-Opitz syndrome (BOS) is a heterogeneous genetic condition characterized by severe developmental delay, characteristic craniofacial appearance, fixed contractures of the upper limbs, abnormal posture, feeding difficulties, severe intellectual disability, fetal microsomia, and failure to thrive ([@bib5], [@bib12], [@bib23]). Most patients die in early childhood due to developmental deficits, unexplained bradycardia, obstructive apnea, or pulmonary infections ([@bib12]). In 2011, [@bib13] identified de novo nonsense mutations of the additional sex combs-like 1 gene (*ASXL1*) in patients with BOS. Somatic *ASXL1* alterations have also been reported in elderly patients with myeloid malignancies, including myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia ([@bib7], [@bib11]).

ASXL1 belongs to the enhancer of trithorax group (TrxG) and polycomb group (PcG) (ETP), and genetically interacts with CBX2 in mice ([@bib10]). PcG and trxG proteins are key regulators for the expression of numerous developmental genes by silencing or activating gene expression, respectively. The ETP genes encode proteins required for both maintenance of activation and silencing, as shown by simultaneous anterior and posterior transformations caused by failure to activate or repress *Hox* genes. In an *Asxl1* mutant mouse model, [@bib10] reported an alteration of the axial skeleton in newborn pups involving anterior and posterior transformations. However, the cellular and molecular mechanisms by which *ASXL1* mutation causes BOS remain unclear.

We have recently reported that *Asxl1* null mice are smaller in size and exhibit anophthalmia ([@bib39]). In this study, we aimed to unveil the cellular and molecular mechanisms underlying the pathogenesis of *ASXL1* loss-mediated skeletal defects. Our study demonstrated that nullizygous loss of *Asxl1* led to multiple skeletal developmental defects, including runting, markedly reduced bone mineral density (BMD), microcephaly, and hypoplastic supraorbital ridges, closely reminiscent of BOS. We further identified that the defective skeletal development was associated with an impaired self-renewal and skewed lineage commitment of BMSCs, away from osteoblast and favoring adipocyte differentiation. Moreover, RNA-sequencing (RNA-seq) analysis demonstrated that *Asxl1* loss altered the expression of genes that are critical for stem cell self-renewal. Importantly, re-introduction of *Asxl1* into *Asxl1*^*−*/*−*^ BMSCs restored BMSC self-renewal and lineage commitment. These data indicate a pivotal role of ASXL1 in the maintenance of BMSC functions and skeletal development.

Results {#sec2}
=======

Loss of *Asxl1* Impairs BMSC Self-Renewal and Differentiation Capacity {#sec2.1}
----------------------------------------------------------------------

Self-renewal and multi-lineage differentiation are the two key characteristics of BMSCs. We first assessed whether *Asxl1* loss alters BMSC cellular functions. qPCR was performed to ensure that *Asxl1* was successfully deleted. While *Asxl1* mRNA was detected in wild-type (WT) BMSCs, no *Asxl1* mRNA was detected in *Asxl1*^*−*/*−*^ BMSCs, indicating successful deletion of *Asxl1* ([Figure S1](#mmc1){ref-type="supplementary-material"}A). *Asxl1* null mice were generated by replacing part of the *Asxl1* exon 1 sequence with *nlacZ*/*nGFP* (inserted 6 bp upstream of the start codon) as previously reported ([@bib39]). The targeted allele results in transcription of *nGFP* mRNA instead of *Asxl1* (the endogenous ATG was disrupted). We examined GFP expression in the BMSCs from *Asxl1*^*+*/*−*^ mice by flow-cytometric analysis to determine whether *Asxl1* is expressed in BMSCs. The CD45^−^CD105^+^CD44^+^CD73^+^CD146^+^CD90^+^ cell population, defined as BMSCs ([@bib3], [@bib17]), were GFP positive ([Figure S1](#mmc1){ref-type="supplementary-material"}B), suggesting expression of ASXL1 in BMSCs.

Having confirmed ASXL1 expression in WT BMSCs, we next examined the effect of *Asxl1* deletion on BMSC expansion. \[^3^H\]Thymidine incorporation assays revealed that *Asxl1* ablation diminished BMSC proliferation ([Figure 1](#fig1){ref-type="fig"}A). [@bib21] reported that Nestin^+^ BMSCs form non-adherent mesenspheres that can be serially re-plated in culture due to their self-renewal capability. We next performed clonal mesensphere cultures to determine whether loss of *Asxl1* altered BMSC self-renewal capacity. The clonal mesensphere formation potential of *Asxl1*^*−*/*−*^ BMSCs was significantly reduced compared with WT BMSCs when equal numbers of BMSCs were plated ([Figure 1](#fig1){ref-type="fig"}B). WT mesenspheres were 414 ± 28.5 μm in diameter and the secondary spheres were 133 ± 20 μm in diameter ([Figures 1](#fig1){ref-type="fig"}C and 1D). In contrast, *Asxl1*^*−*/*−*^ mesenspheres were significantly smaller (187.5 ± 24 μm in diameter) and exhibited a decreased capacity to form secondary spheres (64 ± 4 μm in diameter) ([Figures 1](#fig1){ref-type="fig"}C and 1D). Flow cytometric analysis revealed that the cells of the mesensphere colonies were Nestin^+^, CD51^+^, CD105^+^, and CD146^+^ ([Figure S1](#mmc1){ref-type="supplementary-material"}C), confirming that these cells were indeed BMSCs.

BMSCs have multi-lineage differentiation potential, including the ability to form osteoblasts and adipocytes ([@bib27]). To evaluate the effect of *Asxl1* deletion on BMSC differentiation, we performed osteoblast and adipocyte differentiation assays. Liquid culture of BMSCs with different culture conditions verified that *Asxl1* deletion diminished osteoblast differentiation, as evidenced by minimal alkaline phosphatase-positive (ALP^+^) expression and increased oil red O-positive (^+^) cells in *Asxl1*^*−*/*−*^ cultures compared with WT cultures ([Figures 1](#fig1){ref-type="fig"}E and 1F, respectively). Chondrocyte differentiation assays showed that *Asxl1* deletion did not affect chondrocyte differentiation from BMSCs (data not shown). Collectively, these data indicate that loss of *Asxl1* impairs BMSC self-renewal and skews BMSC lineage commitment away from osteoblasts but in favor of adipocytes.

*Asxl1* Deletion Reduces BMSC Frequency and Alters BMSC Fates in Mice {#sec2.2}
---------------------------------------------------------------------

To examine whether *Asxl1* deletion alters the BMSC frequency in vivo, we next performed flow cytometric analysis on bone marrow cells stained with a cocktail of antibodies, including CD45, CD44, CD105, CD73, CD146, and CD90 ([@bib3], [@bib17]). A significant reduction in the CD45^−^CD44^+^CD105^+^CD73^+^CD146^+^CD90^+^ BMSC population was observed in the bone marrow of *Asxl1*^*−*/*−*^ mice compared with WT littermates ([Figure 2](#fig2){ref-type="fig"}A). Consistently, colony-forming-unit fibroblast (CFU-F) assay, a well-established method to determine BMSC frequency in vivo, revealed a significantly reduced frequency of CFU-F in *Asxl1*^−/−^ bone marrow compared with WT controls ([Figures 2](#fig2){ref-type="fig"}B and 2C). To determine whether the decreased CFU-F frequency was due solely to the decreased frequency of BMSCs in *Asxl1*^−/−^ bone marrow, we performed CFU-F assays with an equal number of BMSCs. Significantly fewer CFU-F were formed by *Asxl1*^*−*/*−*^ BMSCs compared with WT BMSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}D). These data indicate that *Asxl1* deletion decreases the BMSC pool and their CFU-F forming ability in the bone marrow in vivo.

To further evaluate the effect of *Asxl1* loss on BMSC differentiation in vivo, we subsequently performed CFU-osteoblast and CFU-adipocyte differentiation assays using primary bone marrow mononuclear cells (BMMNCs) from WT and *Asxl1*^*−*/*−*^ mice. Compared with WT controls, *Asxl1*^*−*/*−*^ BMMNCs gave rise to a significantly reduced number of ALP^+^ osteoblastic colonies ([Figure 2](#fig2){ref-type="fig"}D). In contrast, the total number of oil red O^+^ colonies and the ratio of oil red O^+^ colonies to CFU-F were dramatically increased in *Asxl1*^*−*/*−*^ cultures ([Figure 2](#fig2){ref-type="fig"}E). Collectively, these data indicate that loss of *Asxl1* impairs BMSC self-renewal and skews BMSC lineage commitment in vivo ([Figure 2](#fig2){ref-type="fig"}F).

Genetic Deletion of *Asxl1* Leads to Multiple Skeletal Deficits Reminiscent of Human Bohring-Opitz Syndrome {#sec2.3}
-----------------------------------------------------------------------------------------------------------

*Asxl1-*knockout mice are smaller in size, and some mice have anophthalmia ([@bib39]). Using alizarin red S/Alcian blue 8GX staining, we showed that loss of *Asxl1* resulted in ∼30% reduction in body size compared with littermate controls ([Figure S2](#mmc1){ref-type="supplementary-material"}A). A kinetic quantitative measurement of body size and body weight revealed significant delays in growth of *Asxl1*^*−*/*−*^ mice over time compared with WT littermates ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). *Asxl1*^*−*/*−*^ mice also exhibited a significant reduction in skull size compared with their littermate controls, reminiscent of the microcephaly in BOS patients ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Peripheral dual-energy X-ray absorptiometry (pDEXA) revealed significantly reduced BMD in the distal femurs of *Asxl1*^*−*/*−*^ mice compared with their littermate controls ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Microcomputed tomography (μCT) demonstrated a marked reduction of bone volume fraction in *Asxl1*^*−*/*−*^ mice compared with their littermate controls ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Furthermore, hypoplastic supraorbital ridges, a characteristic of BOS, were observed in *Asxl1*^*−*/*−*^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}G).

Labeling bones with fluorochrome markers provides a method to study the dynamic changes of bone formation ([@bib40], [@bib45]). We next examined bone remodeling in WT and *Asxl1*^*−*/*−*^ mice with a fluorescent labeling assay. An ∼45% reduction in the bone formation rate per bone surface (BFR/BS) was observed in *Asxl1*^*−*/*−*^ mice compared with WT control mice ([Figures S2](#mmc1){ref-type="supplementary-material"}H and S2I). These data demonstrate that loss of *Asxl1* in mice impairs skeletal development.

Conditional Deletion of *Asxl1* in Osteoblasts Recapitulates the Developmental Defects Observed in *Asxl1*^*−*/*−*^ Mice {#sec2.4}
------------------------------------------------------------------------------------------------------------------------

To further delineate the cell-autonomous role of ASXL1 in mediating BMSC cellular functions, we crossed *Asxl1* floxed allele mice (*Asxl1*^*fl*/*fl*^) ([@bib2]) with transgenic mice harboring *Osterix-Cre* (*Osx-Cre*, specifically expressed in the pre-osteoblastic and osteoblastic lineages) to generate *OsxCre*;*Asxl1*^*fl*/*fl*^ mice (*OsxCre*;*Asxl1*^*Δ*/*Δ*^) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Similar to *Asxl1*^*−*/*−*^ mice, X-ray images of *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice at 3 weeks of age demonstrated dwarfism compared with *Asxl1*^*fl*/*fl*^ control mice ([Figure 3](#fig3){ref-type="fig"}A). Serial measurement of body weight revealed a consistently lower body weight at varying ages of *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with age-matched littermate control mice ([Figure 3](#fig3){ref-type="fig"}B). pDEXA scans demonstrated reduced whole-body BMD and distal femoral BMD in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with their littermate controls ([Figures S3](#mmc1){ref-type="supplementary-material"}B and [3](#fig3){ref-type="fig"}C). μCT further revealed diminished trabecular bone volume and trabecular number along with increased trabecular spacing in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with WT controls ([Figures 3](#fig3){ref-type="fig"}D, 3E, and [S3](#mmc1){ref-type="supplementary-material"}C). In addition, the cortical bone thickness of the mid-shaft femur was significantly reduced compared with control mice ([Figure S3](#mmc1){ref-type="supplementary-material"}D). A greater than 50% reduction in the mineral apposition rate and a 43% reduction in the BFR/BS were observed in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with control mice ([Figures 3](#fig3){ref-type="fig"}F and 3G). These data reinforce the cell-autonomous role of *Asxl1* deletion in defective skeletal development.

To determine whether the BMSC frequency is affected in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice, we examined the percentage of PDGFRα^+^CD45^−^TER119^−^CD31^−^ BMSCs by flow cytometry ([@bib43], [@bib47]). A significant reduction in BMSCs was observed in the bone marrow of *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with littermate controls ([Figures 3](#fig3){ref-type="fig"}H and [S3](#mmc1){ref-type="supplementary-material"}E). PDGFRα^+^CD45^−^TER119^−^CD31^−^ BMSCs from *OsxCre*;*Asxl1*^*Δ*/*Δ*^ and controls contained a similar proportion of Sca1^+^ and CD51^+^ cell populations ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Consistently, a significant reduction in frequency of CFU-F was observed in the bone marrow of *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with littermate control mice ([Figure 3](#fig3){ref-type="fig"}I). When plating an equal number of cells from CFU-F, we found a significant reduction of plating efficiency in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ BMSCs compared with control BMSCs ([Figure S3](#mmc1){ref-type="supplementary-material"}F), suggesting an impaired self-renewal capacity in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice. CFU-osteoblast differentiation assays further confirmed that BMMNCs from *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice gave rise to a significantly reduced number of ALP^+^ osteoblastic colonies than those of control mice ([Figure 3](#fig3){ref-type="fig"}J). The ratio of ALP^+^ osteoblast colonies to total colonies was significantly decreased in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with control mice, further confirming the impaired osteoblast differentiation in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice ([Figure 3](#fig3){ref-type="fig"}K). Collectively, these data further validate our finding that loss of *Asxl1* decreases the BMSC pool and impairs osteoblast differentiation.

*Asxl1* Loss Dysregulates Transcriptional Programs to Induce BMSC Lineage Commitment {#sec2.5}
------------------------------------------------------------------------------------

To determine whether loss of *Asxl1* alters gene expression profiles in BMSCs, we next performed RNA-seq on WT and *Asxl1*^*−*/*−*^ BMSCs. Compared with WT BMSCs, *Asxl1*^*−*/*−*^ BMSCs exhibited a distinct gene expression signature with a total of 338 dysregulated genes. Among those, 182 genes were upregulated and 156 genes downregulated ([Figure 4](#fig4){ref-type="fig"}A). Gene ontology (GO) analysis and enrichment mapping ([@bib22], [@bib26]) demonstrated that the downregulated genes in *Asxl1*^*−*/*−*^ BMSCs were enriched in skeletal development and morphogenesis ([Figure 4](#fig4){ref-type="fig"}B). Furthermore, gene set enrichment analysis (GSEA) ([@bib33]) indicated that loss of *Asxl1* significantly decreased expression of stem cell signature genes in BMSCs ([Figure 4](#fig4){ref-type="fig"}C). By contrast, upregulated genes were enriched in cell development/differentiation and tissue morphogenesis ([Figure S4](#mmc1){ref-type="supplementary-material"}).

To further validate the altered expression of key genes required for BMSC self-renewal and differentiation, we performed qPCR and western blotting with WT and *Asxl1*^*−*/*−*^ BMSCs. qPCR revealed that the mRNA expression of genes critical for stem cell pluripotency, including *Nanog*, *Pou5f1*, and *Sox2*, was significantly reduced in *Asxl1* null BMSCs compared with WT BMSCs ([Figure 4](#fig4){ref-type="fig"}D), correlating with the impaired self-renewal of *Asxl1* null BMSCs. Consistently, western blot analysis revealed markedly reduced NANOG, OCT4, and SOX2 protein levels in *Asxl1* null BMSCs compared with WT cells ([Figure 4](#fig4){ref-type="fig"}E). Furthermore, mRNA expression of *Runx2*, *Sp7*, *Bglap*, and *Alpl*, genes critical for osteogenic differentiation, was also reduced in *Asxl1* null BMSCs compared with WT BMSCs ([Figure 4](#fig4){ref-type="fig"}F). By contrast, mRNA expression of *Pparγ*, *Cebpα*, *Fabp4*, and *Lpl*, genes controlling adipogenic differentiation, was dramatically increased in *Asxl1*-deficient BMSCs compared with WT BMSCs ([Figure 4](#fig4){ref-type="fig"}G). Altogether, these data suggest that ASXL1 regulates BMSC fates through controlling the expression of genes critical for BMSC self-renewal and lineage commitment.

Re-expression of *Asxl1* Rescues Self-Renewal and Osteoblast/Adipocyte Differentiation in *Asxl1*^*−*/*−*^ BMSCs {#sec2.6}
----------------------------------------------------------------------------------------------------------------

To determine whether impaired self-renewal of *Asxl1*^*−*/*−*^ BMSCs was a direct consequence of the *Asxl1* loss, we transduced WT *Asxl1* (with a FLAG tag for easy detection) into *Asxl1*^*−*/*−*^ BMSCs using a lentiviral system. *Asxl1*^*−*/*−*^ BMSCs transduced with empty vector were used as a control. The expression of ASXL1 was confirmed by western blot analysis ([Figure 5](#fig5){ref-type="fig"}A) and qPCR ([Figure S5](#mmc1){ref-type="supplementary-material"}). Re-expression of WT *Asxl1* in *Asxl1*^*−*/*−*^ BMSCs significantly increased mesensphere size ([Figure 5](#fig5){ref-type="fig"}B) and restored levels of NANOG and OCT4 ([Figure 5](#fig5){ref-type="fig"}C), suggesting a restoration of self-renewal capacity of *Asxl1* null BMSCs.

To determine whether re-expression of *Asxl1* could rescue the aberrant lineage commitment of *Asxl1*^*−*/*−*^ BMSCs, we repeated the osteoblast and adipocyte differentiation assays. Re-expression of *Asxl1* in *Asxl1*^*−*/*−*^ BMSCs increased osteoblast differentiation ([Figure 5](#fig5){ref-type="fig"}D) while inhibiting adipocyte differentiation ([Figure 5](#fig5){ref-type="fig"}E) compared with empty vector controls. qPCR confirmed that the expression levels of genes controlling osteoblast and adipocyte differentiation, including *Runx2*, *Sp7*, *Pparγ*, and *Cebpα*, were restored ([Figures 5](#fig5){ref-type="fig"}F and 5G).

Discussion {#sec3}
==========

De novo nonsense mutations of *ASXL1* account for approximately 75% of BOS cases ([@bib13], [@bib19], [@bib30]). This disease is fatal, and the underlying cellular and molecular mechanisms remain unknown. Here, we report that global loss of *Asxl1* or conditional deletion in osteoblasts and their progenitors leads to multiple developmental defects, including dwarfism, hypoplastic supraorbital ridges, microcephaly, low bone mass, and growth retardation. In addition, *Asxl1* loss impairs self-renewal capacity and skews differentiation away from osteoblasts while in favor of adipocytes. Furthermore, deletion of *Asxl1* dysregulates the expression of genes controlling BMSC fates. Our study, therefore, demonstrates a pivotal role of ASXL1 in bone homeostasis.

The balance between BMSC self-renewal and differentiation is critical for skeletal homeostasis ([@bib16], [@bib31]). In this study, we found that *Asxl1* null mice exhibited markedly reduced frequencies of BMSCs and CFU-F. *Asxl1* loss in BMSCs reduced mesensphere formation and diminished re-plating capability, indicating impaired BMSC self-renewal. The frequency of CFU-F in *Asxl1*^*−*/*−*^ bone marrow was even lower than the percentage of BMSCs as determined by flow-cytometric analysis. Thus, the dramatic reduction of CFU-F capacity of *Asxl1*^*−*/*−*^ bone marrow is likely a combined effect of both reduced frequency and impaired self-renewal of BMSCs. In vitro differentiation assays also revealed markedly reduced osteoblast differentiation potential in *Asxl1*^*−*/*−*^ BMSCs. In contrast, *Asxl1*^*−*/*−*^ BMSCs exhibited an increased propensity for adipocyte differentiation, which is consistent with previous findings demonstrating that ASXL1 negatively regulates adipogenesis in a 3T3-L1 cell line ([@bib24]). These results implicate ASXL1 as a critical regulator of BMSC self-renewal and lineage commitment, providing a cellular mechanism underlying defective skeletal homeostasis associated with the *Asxl1* deletion. *ASXL1* mutations occur de novo in BOS patients, and it is therefore expected that multiple cell lineages are affected. To date, however, the specific cell lineages harboring *ASXL1* mutations in BOS patients remain unknown, and further clinical studies are warranted.

The phenotype and fate of a given cell relies on the precise control of gene expression by complex transcriptional and epigenetic networks. Such regulation of gene expression is essential for proper differentiation, cellular function, development, and homeostasis ([@bib9], [@bib28]). Histone modifications are complex, post-translational regulatory events that play pivotal roles in governing global gene expression programs. Although extensive studies have focused on the identification of intrinsic targets of transcription factors regulating cellular fate and functions of BMSCs, the epigenetic events that control BMSC identity and/or functions remain largely unknown. In vitro studies indicate that histone modifications (including methylation and acetylation) are a key epigenetic means for gene regulation that contribute to osteogenic lineage determination ([@bib29], [@bib35]).

ASXL1 regulates epigenetic marks and transcription through interaction with polycomb complex proteins and various transcription activators and repressors ([@bib6], [@bib8], [@bib32]). We and others have previously reported that loss of *Asxl1* reduces global H3K27me3 and H3K4me3 levels in myeloid progenitor cells ([@bib1], [@bib2], [@bib39]). Further studies aiming to identify the chromatin and histone markers governing gene transcription for self-renewal and lineage-specific activation or repression in *Asxl1* deleted BMSCs are ongoing.

Manipulation of epigenetic mechanisms holds great promise for the future treatment of metabolic bone diseases, cancer, and a multitude of other human disease states. A better understanding of the epigenetic regulation in these processes is required for the development of potential pharmacological agents with sufficient specificity to precisely modulate chromatin remodeling on a global scale. The *Asxl1*-deficient murine model provides a compelling system to achieve such insights in the context of the human disease BOS, for which the underling molecular basis was previously unknown.

Experimental Procedures {#sec4}
=======================

*ASXL1* Murine Models {#sec4.1}
---------------------

The generation of *Asxl1*:*nlacZ*/*nGFP* knockin and *Asxl1*^*fl*/*fl*^ mice has been previously described ([@bib2], [@bib39]). *Osx-Cre* transgenic mice were purchased from Jackson Laboratories. All mice were bred on a C57BL/6 genetic background. All protocols were approved by the Institutional Animal Care and Use Committee at University of Miami Miller School of Medicine.

BMSC Culture and Lineage Differentiation Assays {#sec4.2}
-----------------------------------------------

BMSCs were generated from each experimental group of mice as previously described ([@bib44]). In brief, BMSCs were separated by low-density gradient centrifugation from 3- to 4-week-old mice and then resuspended and cultured in mouse MesenCult medium (MesenCult basal media plus 20% of MesenCult Supplemental; Stem Cell Technologies) at 37°C and 5% CO~2~. When the cultures reached 80%--90% confluence, cells were trypsinized and re-plated. BMSCs of identical passage number (between passages 3 and 5) were used for experiments.

For osteoblast differentiation, 5 × 10^4^ BMSCs were cultured for 7 days in 6-well plates using osteogenic differentiation medium (MesenCult medium supplemented with 10^−7^ M dexamethasone, 50 μg/ml ascorbic acid, and 10 mM β-glycerophosphate). For induction of adipocyte differentiation in vitro, 1 × 10^5^ BMSCs were plated in 6-well tissue-culture plates and cultured with adipogenic differentiation medium (MesenCult medium supplemented with 10^−7^ M dexamethasone, 450  μM isobutylmethylxanthine, 1 μg/ml insulin, and 200 μM indomethacin). For chondrocyte differentiation assays, 1 × 10^5^ BMSCs were plated in 6-well plates and cultured with chondrogenic differentiation medium (osteogenic differentiation medium supplemented with 10 ng/ml transforming growth factor β3).

Mesensphere Assays {#sec4.3}
------------------

For clonal mesensphere formation, BMSCs were plated at clonal density (∼1,000 cells/cm^2^) in ultralow adherent 24-well plates (Corning) as previously described ([@bib21], [@bib25]). The growth medium contained 15% chicken embryo extract (Fisher Scientific), 0.1 mM β-mercaptoethanol, 1% non-essential amino acids, 1% N2 and 2% B27 supplements (Gibco), basic fibroblast growth factor, insulin-like growth factor-1, epidermal growth factor, platelet-derived growth factor, and oncostatin M (Peprotech) (20 ng/ml) in DMEM/F12 (1:1)/human endothelial (Gibco) (1:2). The cultures were maintained at 37°C in a 5% CO~2~ water-jacketed incubator and left untouched for 1 week to prevent cell aggregation in low-density cultures. Half of the medium was changed weekly. The mesensphere colonies were detached with trypsin, and the cells were mechanically dispersed and re-plated back into ultralow adherent plates with culture medium. Secondary mesenspheres were counted after 7 days in culture.

Generation of Stably *Asxl1-*Transduced BMSCs {#sec4.4}
---------------------------------------------

The full-length mouse *Asxl1* cDNA with an N-terminal FLAG tag was cloned and then subcloned into the lentiviral vector. The empty vector was used as a control. All constructs were validated by direct sequencing prior to lentiviral generation. BMSCs were split approximately 16 hr prior to transduction and then transduced overnight with concentrated supernatants. Medium was replaced the next day, and transduced cells were cultured and expanded. EGFP^+^ cells were sorted using a FACS Vantage flow cytometer. Before further experiments, transduction and selection efficiency were verified by qPCR and western blot analysis.

Gene Expression Analysis by qPCR and RNA-Seq {#sec4.5}
--------------------------------------------

Gene of interest mRNA levels were determined by real-time qPCR. Total RNA was extracted with TRIzol reagent (Ambion). qPCR was performed in triplicate using an ABI 7500 with SYBR Green PCR kits (Applied Biosystems). mRNA levels were normalized to housekeeping gene *β-actin* expression. All qPCR primers used are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

RNA-Seq reads were aligned to the mouse genome reference sequence (GRCm38/mm10) using TopHat ([@bib37]) with a tolerance of two mismatches. Cuffdiff ([@bib37]) was used to detect the differentially expressed genes with a cutoff of p \< 0.05 and false discovery rate (FDR) \< 0.25. The identified differentially expressed genes were used for pathway enrichment analysis and functional annotation with the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources ([@bib14]). Heatmaps were generated in R using the gplot package. GSEA ([@bib33]) was performed in MSigDB to generate the list of the most differentially expressed genes, including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway signatures and stem cell signatures. Enriched gene sets were selected using a cutoff of p \< 0.05 and FDR \< 0.25 ([@bib15]).

Western Blot Analysis {#sec4.6}
---------------------

BMSC cell lysates were subjected to western blot analysis. Isolated proteins were fractionated using NuPAGE 4%--12% Bis-Tris Gels (Invitrogen) and electrotransferred to polyvinylidene fluoride membranes (Roche). Immunoblots were performed using specific antibodies ([Table S2](#mmc1){ref-type="supplementary-material"}). After incubation with anti-rabbit immunoglobulin G (IgG) or anti-mouse IgG (GE Healthcare) antibodies conjugated with horseradish peroxidase, signals were detected using ECL Chemiluminescence Substrate (Pierce).

Statistical Analysis {#sec4.7}
--------------------

Differences between experimental groups were determined by Student\'s t test or ANOVA followed by Newman-Keuls multiple comparison tests as appropriate. p Values of less than 0.05 were considered significant.
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![*Asxl1* Is Required for BMSC Self-Renewal and Differentiation\
(A) Proliferation assays show impaired growth of *Asxl1*^*−*/*−*^ BMSCs compared with WT (n = 4 mice per genotype from at least three independent experiments).\
(B) The frequency of non-adherent mesenspheres from *Asxl1*^*−*/*−*^ BMSCs is significantly decreased compared with WT BMSCs. An equal number of BMSCs were plated (n = 5 mice per genotype from three independent experiments).\
(C) Self-renewal capacity of BMSCs was assayed by clonal non-adherent sphere formation. *Asxl1*^*−*/*−*^ BMSCs (n = 10 mice) exhibit a significantly decreased sphere diameter compared with WT BMSCs (n = 8 mice). Scale bar represents 100 μm.\
(D) The formation of secondary spheres from *Asxl1*^*−*/*−*^ BMSCs is also significantly reduced compared with WT BMSCs (n = 5 mice per genotype).\
(E) ALP staining shows significantly decreased osteoblast differentiation by *Asxl1*^*−*/*−*^ BMSCs (n = 11 mice) as compared with WT BMSCs (n = 9 mice).\
(F) Oil red O staining shows significantly increased adipocyte differentiation by *Asxl1*^*−*/*−*^ BMSCs compared with WT BMSCs (n = 11 mice per genotype). Scale bar represents 50 μm.\
Data are presented as mean ± SEM. ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Loss of *Asxl1* Impairs BMSC Self-Renewal and Differentiation in Mice\
(A) Quantitation of percentage of CD45^−^CD105^+^CD44^+^CD73^+^CD146^+^CD90^+^ cell populations (BMSCs) in the bone marrow of WT (n = 9 mice) and *Asxl1*^*−*/*−*^ (n = 10 mice, 3 weeks old) by flow cytometry.\
(B and C) The frequencies of CFU-F per femur (B) and per 1 × 10^6^ BMMNCs (C) from WT and *Asxl1*^*−*/*−*^ mice are shown (n = 6 mice per genotype).\
(D) The frequencies of CFU-osteoblast (ALP^+^) per femur are shown (top panel). Representative ALP staining of WT and *Asxl1*^*−*/*−*^ osteoblastic colonies cultured in osteogenic culture medium from BMMNCs. WT (n = 8 mice) and *Asxl1*^*−*/*−*^ (n = 7 mice).\
(E) The ratio of oil red O^+^ adipocytes to total colonies demonstrates enhanced adipocyte differentiation in *Asxl1*^*−*/*−*^ BMSCs compared with WT BMSCs (n = 3 mice per genotype). Scale bar represents 200 μm.\
(F) Pie chart illustrates that loss of *Asxl1* impairs BMSC self-renewal and skews BMSC lineage commitment away from osteoblasts, favoring adipocytes. Data represent the means of four independent experiments.\
Data are presented as mean ± SEM. ^∗∗∗^p \< 0.001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Loss of *Asxl1* in Pre-osteoblasts and Their Progenies Leads to BOS-like Phenotypes in Mice\
(A) High-resolution X-ray images demonstrate runting of *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice compared with *Asxl1*^*fl*/*fl*^ littermates at 3 weeks of life.\
(B) Serial body weight measurement of *OsxCre*;*Asxl1*^*Δ*/*Δ*^ mice and *Asxl1*^*fl*/*fl*^ littermates (n = 6 mice per genotype). Mice were weighed weekly on the same date and time.\
(C) Distal femur BMD of 3-week-old *Asxl1*^*fl*/*fl*^ (n = 4 mice) and *OsxCre*;*Asxl1*^*Δ*/*Δ*^ (n = 6 mice).\
(D and E) μCT analysis shows a significantly reduced bone volume (D) and trabecular bone (E) in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ (n = 6 mice) compared with *Asxl1*^*fl*/*fl*^ controls (n = 4 mice). Scale bar represents 200 μm.\
(F and G) Dynamic bone histomorphometry was performed using alizarin labeling. The mineral apposition rate (MAR, F) and bone formation rate (BFR/BS, G) are significantly decreased in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ (n = 6 mice) versus controls (n = 4 mice). Scale bar represents 20 μm.\
(H) Quantitation of percentage of PDGFRα^+^CD45^−^TER119^−^CD31^−^ BMSCs in the bone marrow of *OsxCre*;*Asxl1*^*Δ*/*Δ*^ (n = 5 mice) and littermate controls (n = 4 mice, 5 weeks old).\
(I) The frequencies of CFU-F per femur from *Asxl1*^*fl*/*fl*^ (n = 5 mice) and *OsxCre*;*Asxl1*^*Δ*/*Δ*^ (n = 7 mice) are shown.\
(J) The frequencies of CFU osteoblasts per femur are shown (top panel). Representative ALP staining of osteoblastic colonies cultured in osteogenic culture medium from *OsxCre*;*Asxl1*^*Δ*/*Δ*^ (n = 5 mice) and *Asxl1*^*fl*/*fl*^ (n = 3 mice) BMMNCs.\
(K) Ratio of ALP^+^ osteoblasts to total colonies demonstrates impaired osteoblast differentiation in *OsxCre*;*Asxl1*^*Δ*/*Δ*^ (n = 5 mice) compared with littermate controls (n = 3 mice).\
Data are presented as mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.001. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![*Asxl1* Deletion Alters the Expression of Genes Critical for BMSCs Self-Renewal and Differentiation\
(A) The heatmap shows clustering of differentially expressed genes between WT and *Asxl1*^*−*/*−*^ BMSCs (p \< 0.05, FDR \< 0.25). Light purple and light blue indicate 182 up- and 156 downregulated genes, respectively.\
(B) The enrichment map helps visualize the network of KEGG pathways and GO terms enriched with downregulated genes in *Asxl1*^*−*/*−*^ BMSCs. Nodes and ovals indicate enriched functional gene sets (p \< 0.01 and FDR \< 0.25 in DAVID) and functional clusters, respectively. Edges indicate overlap between the enriched gene sets; thickness represents significance. Only edges with a Fisher\'s exact test nominal p value smaller than 10^−4^ were visualized. Color intensity is proportional to enrichment significance.\
(C) The GSEA plot shows decreased gene expression of the embryonic stem cell signature ([@bib42]) in *Asxl1*^*−*/*−*^ BMSCs compared with WT BMSCs. The normalized enrichment score (NES), p value, and FDR are shown.\
(D) qPCR analysis shows that expression levels of the pluripotent marker genes *Nanog*, *Pou5f1*, and *Sox2* are significantly lower in *Asxl1*^*−*/*−*^ BMSCs than in WT BMSCs (n = 6 mice per genotype).\
(E) Western blot analysis shows that the protein levels of NANOG, OCT4, and SOX2 are decreased in *Asxl1*^*−*/*−*^ BMSCs compared with WT BMSCs.\
(F) qPCR analysis shows decreased expression levels of the osteoblast marker genes (*Runx2*, *Bglap*, *Sp7*, and *Alpl*) in *Asxl1*^*−*/*−*^ BMSCs versus WT BMSCs (n = 10 mice per genotype).\
(G) qPCR analysis shows significantly increased expression of the adipocyte marker genes (*Pparγ*, *Cepbα*, *Fabp4*, and *Lpl*) in *Asxl1*^*−*/*−*^ BMSCs compared with WT BMSCs (n = 4 mice per genotype).\
Data are presented as mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Re-expression of ASXL1 Rescues the Aberrant Cellular Phenotypes of *Asxl1*^*−*/*−*^ BMSCs\
(A) Western blot analysis shows the expression of FLAG-ASXL1 protein in *Asxl1*^*−*/*−*^ BMSCs transduced with empty vector control or ASXL1 expression vector (FLAG*-Asxl1*).\
(B) Mesensphere assay shows the self-renewal capacity of WT and *Asxl1*^*−*/*−*^ BMSCs expressing either empty vector or FLAG*-Asxl1* as indicated. Top bars represent the mean mesensphere diameter (μm) from three independent experiments. Representative mesensphere photomicrographs are labeled accordingly. Scale bar represents 200 μm.\
(C) Western blot analysis for NANOG and OCT4 in WT and *Asxl1*^*−*/*−*^ BMSCs expressing either empty vector or FLAG*-Asxl1*.\
(D) ALP staining of osteoblast cultures of WT BMSCs and *Asxl1*^*−*/*−*^ BMSCs expressing empty vector or FLAG*-Asxl1* as indicated. Top bars represent the relative ALP^+^ activity from four independent experiments. Bottom panel shows representative photomicrographs of ALP staining cultures. Scale bar represents 200 μm.\
(E) Oil red O staining of adipocyte cultures of WT or *Asxl1*^*−*/*−*^ BMSCs expressing either empty vector or FLAG*-Asxl1* as indicated. Top bars represent the number of oil red O^+^ cells in cultures of WT or *Asxl1*^*−*/*−*^ BMSC expressing either empty vector or FLAG*-Asxl1* from four independent experiments. Bottom panel shows representative photomicrographs of oil red O^+^ staining cells. Scale bar represents 50 μm.\
(F) qPCR shows the expression of osteoblast differentiation genes (*Runx2*, *Sp7*, and *Alpl*) in WT and *Asxl1*^*−*/*−*^ BMSCs transduced with FLAG*-Asxl1* or empty vector in six independent experiments.\
(G) qPCR shows the expression of adipocyte differentiation genes in WT and *Asxl1*^*−*/*−*^ BMSCs with or without transduction of FLAG*-Asxl1* from four independent experiments.\
Data are presented as mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}
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